Myasthenia Gravis Drug Shows Benefits in Wider Range of Patients

(MedPage Today) — SAN FRANCISCO — Intravenous efgartigimod (Vyvgart) met its primary endpoint in adults with acetylcholine receptor (AChR) antibody-negative myasthenia gravis, the ADAPT SERON trial showed.
At week 4, Myasthenia Gravis Activities…